Non-ST Elevation Myocardial Infraction after High Dose Intravenous Immunoglobulin Infusion
- PMID: 20182639
- PMCID: PMC2825772
- DOI: 10.1155/2009/861370
Non-ST Elevation Myocardial Infraction after High Dose Intravenous Immunoglobulin Infusion
Abstract
Intravenous immunoglobulins (IVIgs) are used for several indications, including autoimmune conditions. IVIg treatment is associated with several possible adverse reactions including induction of a hypercoagulable state. We report a 76-year-old woman treated with IVIg for myasthenia gravis, which developed chest pain and weakness following IVIg infusion. The symptoms were associated with ST segment depression in V4-6 and elevated troponin levels. The patient was diagnosed with non-ST elevation myocardial infarction (NSTEMI). The patient had no significant risk factor besides age and a cardiac perfusion scan was interpreted as normal (the patient refused to undergo cardiac catheterization). This case is compatible with IVIg-induced hypercoagulability resulting in NSTEMI. Cardiac evaluation should therefore be considered prior to initiation of IVIg treatment especially in patients with multiple cardiovascular risks.
Similar articles
-
Coronary spastic angina after the administration of intravenous immunoglobulin in myasthenia gravis: a case report.BMC Neurol. 2020 Aug 28;20(1):319. doi: 10.1186/s12883-020-01901-2. BMC Neurol. 2020. PMID: 32859168 Free PMC article.
-
Acute ST elevation myocardial infarction during intravenous immunoglobulin infusion.Ann N Y Acad Sci. 2007 Sep;1110:315-8. doi: 10.1196/annals.1423.033. Ann N Y Acad Sci. 2007. PMID: 17911446
-
Myocardial infarction associated with intravenous immune globulin.Ann Pharmacother. 2005 Dec;39(12):2114-8. doi: 10.1345/aph.1G104. Epub 2005 Nov 15. Ann Pharmacother. 2005. PMID: 16288078
-
Contemporary NSTEMI management: the role of the hospitalist.Hosp Pract (1995). 2020 Feb;48(1):1-11. doi: 10.1080/21548331.2020.1701329. Epub 2020 Feb 20. Hosp Pract (1995). 2020. PMID: 31815570 Review.
-
Intravenous immunoglobulin in the treatment of neurologic disorders.Acta Neurol Scand. 2016 Feb;133(2):84-96. doi: 10.1111/ane.12444. Epub 2015 May 21. Acta Neurol Scand. 2016. PMID: 25997034 Review.
Cited by
-
Advances in sulodexide-based long-term anticoagulation for a myasthenia gravis patient with giant thymoma.Front Pharmacol. 2025 Feb 26;16:1543612. doi: 10.3389/fphar.2025.1543612. eCollection 2025. Front Pharmacol. 2025. PMID: 40078295 Free PMC article. Review.
-
Non-coronary myocardial infarction in myasthenia gravis: Case report and review of the literature.World J Cardiol. 2013 Jul 26;5(7):265-9. doi: 10.4330/wjc.v5.i7.265. World J Cardiol. 2013. PMID: 23888198 Free PMC article.
-
Mesalamine-induced myocarditis and coronary vasculitis in a pediatric ulcerative colitis patient: a case report.Case Rep Pediatr. 2011;2011:524364. doi: 10.1155/2011/524364. Epub 2011 Dec 21. Case Rep Pediatr. 2011. PMID: 22611512 Free PMC article.
-
Pulmonary edema in myasthenic crisis.Case Rep Crit Care. 2013;2013:863620. doi: 10.1155/2013/863620. Epub 2013 Dec 26. Case Rep Crit Care. 2013. PMID: 24829832 Free PMC article.
-
A practical guide to the management of immune thrombocytopenia co-existing with acute coronary syndrome.Front Med (Lausanne). 2024 Apr 11;11:1348941. doi: 10.3389/fmed.2024.1348941. eCollection 2024. Front Med (Lausanne). 2024. PMID: 38665297 Free PMC article. Review.
References
-
- Vani J, Elluru S, Negi VS, et al. Role of natural antibodies in immune homeostasis: IVIg perspective. Autoimmunity Reviews. 2008;7(6):440–444. - PubMed
-
- Dalakas MC. Intravenous immunoglobulin in autoimmune neuromuscular diseases. Journal of the American Medical Association. 2004;291(19):2367–2375. - PubMed
-
- Gold R, Stangel M, Dalakas MC. Drug insight: the use of intravenous immunoglobulin in neurology—therapeutic considerations and practical issues. Nature Clinical Practice Neurology. 2007;3(1):36–44. - PubMed
-
- Bayry J, Lacroix-Desmazes S, Kazatchkine MD, Kaveri SV. Monoclonal antibody and intravenous immunoglobulin therapy for rheumatic diseases: rationale and mechanisms of action. Nature Clinical Practice Rheumatology. 2007;3(5):262–272. - PubMed
-
- Kamali S, Cefle A, Sayarlioglu M, et al. Experience with monthly, high-dose, intravenous immunoglobulin therapy in patients with different connective tissue diseases. Rheumatology International. 2005;25(3):211–214. - PubMed
Publication types
LinkOut - more resources
Full Text Sources